journal
MENU ▼
Read by QxMD icon Read
search

Clinical & Translational Oncology

journal
https://www.readbyqxmd.com/read/29159793/curative-radiation-therapy-for-very-elderly-bladder-cancer-patients-with-localized-disease
#1
M Bonet, T Bonfill, M Nuñez, L De Verdonces, E Mur, E Gallardo, L Fernandez-Morales, A Aguilar, J Prats, M Arenas
PURPOSE: To report the outcomes of a cohort of very elderly muscle-invasive bladder cancer (MIBC) patients treated with contemporary 3D-conformal radiation therapy (3D-CRT) with or without concurrent chemotherapy, after transurethral resection of bladder tumor (TURBT). METHODS: From February 2010 to January 2014, a total of 41 patients older than 75 years, with T2-3 N0-1 high-grade MIBC, a Karnofsky index (KI) of at least 90% and/or a Barthel scale score of at least 95, were treated with TURBT followed by radiotherapy (RT) with or without chemotherapy, and were prospectively followed-up...
November 20, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29159792/seom-clinical-guidelines-for-the-treatment-of-head-and-neck-cancer-2017
#2
L C Iglesias Docampo, V Arrazubi Arrula, N Baste Rotllan, A Carral Maseda, B Cirauqui Cirauqui, Y Escobar, J J Lambea Sorrosal, M Pastor Borgoñón, A Rueda, J J Cruz Hernández
Head and neck cancer (HNC) is defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence obtained since 2013 publication, Spanish Society of Medical Oncology (SEOM) presents an update of HNC diagnosis and treatment guideline. The eighth edition of TNM classification, published in January 2017, introduces important changes for p16-positive oropharyngeal tumours, for lip and oral cavity cancer and for N3 category...
November 20, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29159791/determining-personalized-treatment-by-gene-expression-profiling-in-metastatic-breast-carcinoma-patients-a-pilot-study
#3
M Sureda, J Rebollo, E Mª Martínez-Navarro, F J Fernández-Morejón, J Farré, V Muñoz, P Bretcha-Boix, M Duarte, R G Manzano, A Crespo, M Del Carmen Redal, B Valenzuela, A Brugarolas
PURPOSE: The present study evaluates the massive study of gene expression in metastatic breast carcinoma (MBC) patients using microarray gene expression profiling (MAGE) complemented with conventional sequencing, immunohistochemistry (IHC) and fluorescent "in situ" hybridization (FISH), seeking to optimize the treatment in a subset of heavily pretreated patients and with limited life expectancy. PATIENTS, MATERIAL AND METHODS: MBC patients in hormone therapy progression with survival expectancy of at least 3 months (m) have been included...
November 20, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29149431/seom-clinical-guidelines-in-gestational-trophoblastic-disease-2017
#4
A Santaballa, Y García, A Herrero, N Laínez, J Fuentes, A De Juan, V Rodriguez Freixinós, J Aparicio, A Casado, E García-Martinez
Gestational trophoblastic disease (GTD) is a rare but curable disease. Recent improvements in diagnosis and molecular biology have resulted in changes in staging and treatment. These guidelines provide evidence-based recommendation on how to manage GTD.
November 17, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29143229/meta-analysis-of-survival-benefit-with-postoperative-chemoradiotherapy-in-patients-of-lymph-node-positive-esophageal-carcinoma
#5
H Luo, Y Y Cui, J G Zhang, Y N Sun, X L Zheng, C L Yang, K Ye, H Ge
BACKGROUND: The effect of postoperative chemoradiotherapy (CRT) for esophageal carcinoma (EC) was investigated. Patients who can obtain benefit from this treatment modality have not yet been well identified. METHODS: We searched PubMed, Embase, Web of Science, and the Cochrane Library for studies published from January 1993 to July 2016. Research comparing surgery alone (SA) with postoperative CRT in patients with resectable EC was procured; collected articles were written in English...
November 15, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29143228/effect-of-exosome-biomarkers-for-diagnosis-and-prognosis-of-breast-cancer-patients
#6
REVIEW
M Wang, S Ji, G Shao, J Zhang, K Zhao, Z Wang, A Wu
PURPOSE: Exosomes are gradually detected as an indicator for diagnosis and prognosis of breast cancer in clinic and a systematic review was conducted. METHODS: A search for clinical studies published before July 1, 2017 was performed. Methods of exosome purification and identification from all studies were extracted. For diagnosis evaluation, the comparison of exosome biomarkers expression between breast cancer patients and healthy women was obtained; for prognosis prediction, the correlation between exosome biomarkers expression and chemotherapy resistance, overall survival (OS), disease-free survival (DFS), recurrence and metastasis of breast cancer was also extracted...
November 15, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29139040/recommendations-for-the-follow-up-care-of-female-breast-cancer-survivors-a-guideline-of-the-spanish-society-of-medical-oncology-seom-spanish-society-of-general-medicine-semergen-spanish-society-for-family-and-community-medicine-semfyc-spanish-society-for-general
#7
A Barnadas, M Algara, O Cordoba, A Casas, M Gonzalez, M Marzo, A Montero, M Muñoz, A Ruiz, F Santolaya, T Fernandez
The increased incidence and decreased mortality of breast cancer have produced an increased number of breast cancer survivors. The type of sequelae and comorbidities that these patients present call for a collaborative follow-up by hospital-based specialized care and primary care. In this document, we present a guideline drafted and agreed among scientific societies whose members care for breast cancer survivors. The purpose of this guideline is to achieve the shared and coordinated follow-up of these patients by specialized care and primary care professionals...
November 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29139039/genetic-screening-and-molecular-characterization-of-met-alterations-in-non-small-cell-lung-cancer
#8
M Saigi, A McLeer-Florin, E Pros, E Nadal, E Brambilla, M Sanchez-Cespedes
PURPOSE: Aberrant activation of MET as a result of exon 14-skipping (METex14) mutations or gene amplification is an oncogenic mechanism in non-small cell lung carcinoma (NSCLC) and a potential therapeutic target. The purpose of this study was to characterize MET alterations in a cohort of NSCLC patients treated with surgery. METHODS AND PATIENTS: 157 NSCLCs of various histopathologies, including pulmonary sarcomatoid carcinomas (PSC), were tested for MET alterations...
November 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29134564/seom-clinical-guideline-for-treatment-of-kidney-cancer-2017
#9
E Gallardo, M J Méndez-Vidal, J L Pérez-Gracia, J M Sepúlveda-Sánchez, M Campayo, I Chirivella-González, X García-Del-Muro, A González-Del-Alba, E Grande, C Suárez
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma...
November 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29134563/preoperative-plasma-fibrinogen-is-associated-with-poor-prognosis-in-esophageal-carcinoma-a-meta-analysis
#10
REVIEW
G Y Lv, Y Yu, L An, X D Sun, D W Sun
PURPOSE: The aim of this meta-analysis was to investigate preoperative plasma fibrinogen (PPF) as a prognostic marker in esophageal carcinoma (EC) by meta-analysis. METHODS: Relevant studies were sought in the databases including Pubmed, Web of Science, Cochrane library, and Wanfang databases up to Oct 10th, 2017. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were used as effective value, and pooled HRs were synthesized by STATA 14.0 to assess the prognostic impact of PPF on EC patients...
November 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29134562/seom-clinical-guidelines-for-the-treatment-of-metastatic-prostate-cancer-2017
#11
J Cassinello, J Á Arranz, J M Piulats, A Sánchez, B Pérez-Valderrama, B Mellado, M Á Climent, D Olmos, J Carles, M Lázaro
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma...
November 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29127594/morphine-double-faced-roles-in-the-regulation-of-tumor-development
#12
REVIEW
X Y Zhang, Y X Liang, Y Yan, Z Dai, H C Chu
Morphine, a highly potent analgesic, is one of the most effective drugs for the treatment of severe pain associated with cancer. It directly acts on the central nervous system to relieve pain, but also cause secondary complications, such as addiction, respiratory depression and constipation due to its activities on peripheral tissues. Besides pain relief, morphine is of great importance on cancer management with its effect on tumor development being the subject of debate for many years with some contradictory findings...
November 10, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29127593/seom-clinical-guideline-for-treatment-of-cancer-pain-2017
#13
C Jara, S Del Barco, C Grávalos, S Hoyos, B Hernández, M Muñoz, T Quintanar, J A Meana, C Rodriguez, R de Las Peñas
Pain is a highly prevalent symptom in patients with cancer. Despite therapeutic advances and well-accepted treatment guidelines, a percentage of patients with pain are under-treated. Currently, it has been recognized that several barriers in pain management still exist and, in addition, there are new challenges surrounding complex subtypes of pain, such as breakthrough and neuropathic pain, requiring further reviews and recommendations. This is an update of the guide our society previously published and represents the continued commitment of SEOM to move forward and improve supportive care of cancer patients...
November 10, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29124520/seom-clinical-guideline-of-diagnosis-and-management-of-low-grade-glioma-2017
#14
J M Sepúlveda-Sánchez, J Muñoz Langa, M Á Arráez, J Fuster, A Hernández Laín, G Reynés, V Rodríguez González, E Vicente, M Vidal Denis, Ó Gallego
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition of these tumors to include their molecular characterization, including the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19p codeletion. In this new classification, the histologic subtype of grade II-mixed oligoastrocytoma has also been eliminated...
November 9, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29124519/prognostic-and-predictive-role-of-the-pi3k-akt-mtor-pathway-in-neuroendocrine-neoplasms
#15
REVIEW
P Gajate, T Alonso-Gordoa, O Martínez-Sáez, J Molina-Cerrillo, E Grande
Neuroendocrine neoplasms (NENs) are considered a heterogeneous and rare entity. Its natural history is influenced by multiple clinicopathological characteristics, which guide the management of these patients. The development of molecular biology reveals that the PI3K-AKT-mTOR pathway plays a relevant role in tumorigenesis and progression of NENs. Mammalian target of rapamycin (mTOR) inhibitors, targeted agents that block this pathway, has improved outcomes in neuroendocrine tumors (NETs). Different therapeutic approaches, such as somatostatin analogs, chemotherapy, peptide receptor radionuclide therapy, and targeted agents, have shown benefits in the treatment of NETs...
November 9, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29119458/efficacy-of-radioiodine-therapy-for-treating-20-patients-with-pulmonary-metastases-from-differentiated-thyroid-cancer-and-a-meta-analysis-of-the-current-literature
#16
X Zhang, D-S Liu, Z-S Luan, F Zhang, X-H Liu, W Zhou, S-F Zhong, H Lai
BACKGROUND: Radioiodine therapy (RAI) after total or near-total thyroidectomy is a recommended treatment for patients with pulmonary metastasis from differentiated thyroid cancer (DTC). However, the total effective rate of iodine-131 therapy remains controversial. This study aimed to determine the efficacy of RAI for treating patients with pulmonary metastasis from DTC, and to identify independent predictors of its efficacy. METHODS: We conducted a retrospective study to evaluate 20 patients with pulmonary metastasis from DTC who underwent RAI at our center at first and performed a meta-analysis to evaluate relevant literature regarding the overall efficacy of RAI and subgroup-specific efficacies subsequently...
November 8, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29116433/safety-of-everolimus-plus-exemestane-in-patients-with-hormone-receptor-positive-her2-negative-locally-advanced-or-metastatic-breast-cancer-results-of-phase-iiib-ballet-trial-in-spain
#17
E Ciruelos, M Vidal, E Martínez de Dueñas, N Martínez-Jáñez, Y Fernández, J A García-Sáenz, L Murillo, F Carabantes, A Beliera, R Fonseca, J Gavilá
BACKGROUND: Everolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer. It is necessary, therefore, to characterize the safety profile of this new combination in the real-world clinical setting and in the broadest possible population. PATIENTS AND METHODS: Post-menopausal women with HR-positive HER2-negative advanced breast cancer progressing after prior non-steroidal aromatase inhibitors (NSAIs) were included...
November 7, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29116432/seom-clinical-guideline-for-the-management-of-malignant-melanoma-2017
#18
A Berrocal, A Arance, V E Castellon, L de la Cruz, E Espinosa, M G Cao, J L G Larriba, I Márquez-Rodas, A Soria, S M Algarra
All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy...
November 7, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29110217/aggressive-intrahepatic-therapies-for-synchronous-hepatocellular-carcinoma-with-pulmonary-metastasis
#19
Z Hu, P Huang, Z Zhou, W Li, J Xu, K Xu, J Wang, H Zhang
PURPOSE: Prognosis of synchronous hepatocellular carcinoma (HCC) patients with pulmonary metastasis (PM) was poor, while aggressive intrahepatic therapies remained controversial. This study aimed to investigate the significance of aggressive intrahepatic therapies for synchronous PM-HCC. METHODS: Synchronous PM-HCC patients were retrospectively enrolled from Sun Yat-sen Memorial Hospital of Sun Yat-sen University during January 2000 and December 2015. Univariate and multivariate analysis were performed to investigate the prognostic factors...
November 6, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29098557/loc285629-regulates-cell-proliferation-and-motility-in-colorectal-cancer-cells
#20
S N Nasir, N Abu, N S Ab Mutalib, M Ishak, I Sagap, L Mazlan, I M Rose, R Jamal
PURPOSE: Colorectal cancer (CRC) is one of the most widely diagnosed cancers in men and women worldwide. With the advancement of next-generation sequencing technologies, many studies have highlighted the involvement of long non-coding RNAs (lncRNAs) in cancer development. Growing evidence demonstrates that lncRNAs play crucial roles in regulating gene and protein expression and are involved in various cancers, including CRC. The field of lncRNAs is still relatively new and a lot of novel lncRNAs have been discovered, but their functional roles are yet to be elucidated...
November 2, 2017: Clinical & Translational Oncology
journal
journal
41053
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"